Ameren Announces Third Quarter 2026 Results

Ameren reported Q3 2026 GAAP diluted EPS of $2.42, versus $2.35 a year earlier; adjusted EPS was $2.42 versus $2.17, excluding a $48 million 2025 tax benefit. The company raised 2026 EPS guidance by $0.10 at both ends to $5.35–$5.55 and set 2027 guidance of $5.70–$5.90, with 8%–10% annual EPS growth targeted for 2027–2031. Ameren cited $38.1 billion in planned infrastructure investment and approximately 13.3% annual rate-base growth from 2026 through 2031; it expects to grow its common dividend annually, with a 45%–55% payout ratio.

Analysis

The key underwriting question is whether planned rate-base growth converts into allowed, timely earnings without pushing customer bills or financing costs high enough to provoke resistance. This is a capital-intensive growth story, not an equivalent expansion in free cash flow: nine-month capital spending exceeded operating cash flow, while debt issuance and a larger share count point to continued external funding needs. Higher rates or weaker credit metrics could therefore absorb part of the EPS growth through interest expense and dilution.

Near term, the November 6 call is the catalyst: listen for the status and economics of large-load commitments, the Missouri rate review, capital-spending cadence, and funding mix. Weather-supported Missouri sales are a less durable earnings driver than regulated investment returns; the guidance assumes normal temperatures, so the 2026 raise should not be extrapolated mechanically. Over 6–18 months, the upside case depends on regulators allowing cost recovery and projects reaching service on schedule. The counter-risk is that data-center demand and infrastructure spending raise bills before customer additions and approved rates deliver returns, increasing political and regulatory friction. Illinois industrial distribution volumes also warrant monitoring rather than assuming broad-based load acceleration.

Consensus may treat multi-year EPS guidance as a relatively secure utility growth profile; the less appreciated constraint is the interaction of affordability, rate-case timing, and funding costs. There is no basis here to conclude the shares are mispriced without valuation and peer data.

Key Decisions for Investors

• Hold or add AEE only on valuation discipline; do not chase the guidance increase alone. The constructive thesis is regulated investment growth, while the key downside is delayed recovery or a higher cost of capital.
• Use the November 6 call as a near-term verification point: seek specific large-customer load milestones, rate-case timelines, capital funding plans, and evidence that allowed returns are keeping pace with higher interest expense.
• Track quarterly operating cash flow against capital expenditures, debt issuance, share count, and interest expense. A sustained funding gap or rising dilution would weaken the quality of EPS growth even if rate base expands.
• Falsify the bullish thesis if regulators constrain recovery or returns, large-load projects slip, or guidance growth is revised down; strengthen it if rate orders support timely recovery and customer commitments translate into realized load.